KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Working Capital Changes (2020 - 2025)

Recursion Pharmaceuticals' Other Working Capital Changes history spans 6 years, with the latest figure at -$3.0 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 90.7% year-over-year to -$3.0 million; the TTM value through Dec 2025 reached -$36.8 million, down 31.15%, while the annual FY2025 figure was -$36.8 million, 31.15% down from the prior year.
  • Other Working Capital Changes reached -$3.0 million in Q4 2025 per RXRX's latest filing, up from -$10.4 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $41.1 million in Q4 2023 to a low of -$32.2 million in Q4 2024.
  • Average Other Working Capital Changes over 5 years is -$2.7 million, with a median of -$1.4 million recorded in 2021.
  • Peak YoY movement for Other Working Capital Changes: tumbled 425.68% in 2022, then soared 734.17% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.4 million in 2021, then soared by 459.78% to $4.9 million in 2022, then skyrocketed by 734.17% to $41.1 million in 2023, then plummeted by 178.34% to -$32.2 million in 2024, then surged by 90.7% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Other Working Capital Changes are -$3.0 million (Q4 2025), -$10.4 million (Q3 2025), and $3.7 million (Q2 2025).